ERBB2 and breast carcinoma: Our central objective was to examine FOLR1 expression patterns in clinically relevant molecular subtypes of breast cancer (ER+, HER2+, and TNBC) to identify whether there was differential expression, and to explore a potential mechanistic role of FOLR1 in breast cancer cells.